SLC7A11 and neoplasm: We also demonstrated that an xCT selective inhibitor, Sulfasalazine (SASP), which has been approved by FDA for treatment of some inflammatory diseases (Gout et al., 2001), can effectively prevent PEL tumor progression in an immune-deficient xenograft mouse model (Dai et al., 2014a,c), supporting the potential benefit of targeting xCT as a strategy for attenuating progression to overt lymphomagenesis.